A documentary about Elizabeth Holmes, made in secret by Nathan Fielder and Lance Oppenheim, made its surprise debut at the Telluride Film Festival over the weekend, according to TechCrunch. The film, titled "You Can See Everything," reportedly stunned audiences with what the outlet describes as generous access to the Theranos founder.
The arrival of yet another Holmes project might prompt a reasonable question: does the world need more Theranos content? The honest answer is that the question itself misses what makes this one different, and potentially more significant than the considerable body of work that has already accumulated around one of Silicon Valley's most spectacular frauds.
Holmes was convicted in January 2022 on four counts of fraud against investors, and has been serving her prison sentence at a federal facility in Texas. The legal chapter of her story, in other words, is largely closed. What has remained stubbornly open is the interpretive one. John Carreyrou's foundational reporting and subsequent book gave the world the forensic account of how the Theranos deception worked. Adam McKay's HBO documentary and Hulu's dramatized series "The Dropout" examined her psychology and the culture that enabled her rise. Each of those projects had to work around Holmes herself, who was constrained by active legal proceedings and whose cooperation was essentially unavailable. Access was the one thing no previous filmmaker could claim.
That appears to be what changes here. TechCrunch's characterization of the access as generous is the detail that matters most, because it shifts the entire premise of the exercise. A documentary made with Holmes's meaningful participation is a fundamentally different artifact than one constructed from court records, whistleblowers, and former colleagues. Whether that access produces revelation or managed rehabilitation is the central question the film will have to answer for critics and audiences.
The involvement of Nathan Fielder is worth pausing on. Fielder built his reputation on an unusual brand of documentary-adjacent work, most fully realized in his HBO series "The Rehearsal," which used elaborate staged scenarios to probe questions of authenticity, performance, and the ethics of documentary filmmaking itself. His work is almost constitutionally interested in the gap between how people present themselves and who they actually are — and in what happens when a filmmaker's presence begins to shape the story being told. Pairing that sensibility with a subject who is widely understood to have been one of the most deliberate self-constructors in recent American business history is, at minimum, a conceptually rich collision. Lance Oppenheim, whose documentary work has dealt with isolation and the stories people tell themselves to survive, brings a complementary instinct.
The likely reading is that this collaboration was chosen, or at least accepted, by Holmes's team precisely because Fielder's reputation creates ambiguity about what kind of film will emerge. A traditional investigative documentary would offer Holmes little. A Nathan Fielder project offers the possibility of a more elliptical treatment, one where the subject's self-presentation becomes the subject itself, which could serve multiple interests simultaneously. Whether Fielder and Oppenheim have used that ambiguity to get closer to something true, or whether Holmes has used it to get closer to a sympathetic platform, is presumably what Telluride audiences were processing after Sunday's screening.
The consequences ripple outward in a few directions. For Holmes, a well-received documentary capable of generating genuine public sympathy would matter most in the context of any future sentence reduction or parole consideration, and in the longer project of reputation repair that will inevitably follow her release. For the technology industry, any renewed conversation about Holmes tends to reopen uncomfortable questions about the degree to which venture capital culture, prominent board members, and a press hungry for the narrative of a female Steve Jobs collectively enabled a fraud that harmed real patients. That conversation has never fully resolved itself, and a high-profile film keeps it active.
For documentary filmmaking as a form, the project sits in a lineage of works that have had to grapple with what it means to grant a convicted fraudster — or any controversial figure — a camera and a platform. The ethics of access-driven documentary are genuinely contested, and a film with this much attention attached to it will sharpen that debate.
The immediate things to watch are how the film is received as it moves through the festival circuit and toward wider distribution, what reviewers make of the balance between Fielder's formal games and the weight of the subject matter, and whether Holmes herself says or reveals anything that moves the factual record in any direction. The secondary question is how the surviving victims of the Theranos fraud and the journalists who exposed it respond publicly to a documentary that appears to have been built, at least in part, around Holmes's own willingness to participate.
